A consensus statement identifying the best use of plerixafor to facilitate autologous peripheral stem cell collection to support high-dose therapy and stem cell transplantation in myeloma or lymphoma patients has been published recently in the Journal of Clinical Apheresis. Written by the Plerixafor Usage Working Party Group involving representative clinicians from the UK and Republic of Ireland, the article reviews the existing literature on its use in delayed re-mobilisation following previous mobilisation failure and its use in a pre-emptive setting, as well as audit data from the Working Group. The consensus statement identifies those patients who may benefit from plerixafor during stem cell mobilisation and determines the specific criteria for its use.